Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Ooi MG, et al. Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934289 Free PMC article.
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P. O'Connor R, et al. Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. doi: 10.1007/s00280-013-2136-7. Epub 2013 Apr 16. Cancer Chemother Pharmacol. 2013. PMID: 23589314 Free PMC article.
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG. Laubach J, et al. Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29. Leukemia. 2016. PMID: 26710887 Review.
Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.
Ting KR, Brady JJ, Hameed A, Le G, Meiller J, Verburgh E, Bayers C, Benjamin D, Anderson KC, Richardson PG, Dowling P, Clynes M, Fitzgibbon MC, O'Gorman P. Ting KR, et al. Br J Haematol. 2016 Apr;173(1):82-8. doi: 10.1111/bjh.13928. Epub 2016 Jan 20. Br J Haematol. 2016. PMID: 26787413 Free article.
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J. Moreau P, et al. Eur J Haematol. 2017 Sep;99(3):199-206. doi: 10.1111/ejh.12903. Epub 2017 Jun 14. Eur J Haematol. 2017. PMID: 28504846
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. Guang MHZ, et al. Leuk Lymphoma. 2018 Mar;59(3):542-561. doi: 10.1080/10428194.2017.1337115. Epub 2017 Jun 13. Leuk Lymphoma. 2018. PMID: 28610537 Free PMC article. Review.
163 results